Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding DisordersFlora Peyvandi, Frits R. Rosendaal, Roberta Palla et al.|Journal of Thrombosis and Haemostasis|2012Cited by 498
The economics of haemophilia prophylaxis: governmental and insurer perspectives. PROCEEDINGS OF THE SECOND INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) SYMPOSIUMB. M. Feldman, V. Blanchette, Andrea Doria et al.|Haemophilia|2007Cited by 22
ALA‐10 MUTATIONS IN THE FACTOR IX PROPEPTIDE AND HAEMORRHAGE IN A PATIENT TREATED WITH WARFARINPeter Baker, David Keeling, Kevin Clarke et al.|British Journal of Haematology|2000Cited by 10